|1.||Terada, Tadashi: 36 articles (01/2015 - 11/2002)|
|2.||Chopp, Michael: 10 articles (07/2013 - 06/2003)|
|3.||Moran, Cesar A: 9 articles (12/2014 - 12/2002)|
|4.||Suster, Saul: 9 articles (06/2013 - 05/2003)|
|5.||Rekhi, Bharat: 7 articles (10/2015 - 03/2010)|
|6.||Nakazato, Yoichi: 7 articles (01/2014 - 06/2002)|
|7.||Dundr, Pavel: 7 articles (04/2013 - 01/2003)|
|8.||Chen, Jieli: 7 articles (01/2013 - 06/2003)|
|9.||Jambhekar, Nirmala A: 6 articles (10/2015 - 03/2010)|
|10.||Haba, Reiji: 6 articles (09/2014 - 04/2009)|
03/01/2013 - "Immunohistochemical analysis of 15 tumors showed that pure cystic/papillary lesions had a significantly greater percentage of synaptophysin-immunoreactive cells (P = .036). "
01/01/2012 - "Immunohistochemical studies revealed that both tumors were diffusely positive for Synaptophysin and Olig2. "
12/01/2007 - "To study the importance of NB84, synaptophysin and AgNOR and explore the quantitative association of these factors with diagnosis and outcome as well as the association between NB84 and AgNOR and other tumor and stromal factors in twenty-eight peripheral neuroblastic tumors. "
07/01/1991 - "Immunohistochemical studies revealed variable immunoreactivity for simple epithelial cell cytokeratins and for synaptophysin (weak staining) in a minority of tumor cells. "
02/01/1987 - "It is concluded that synaptophysin is a significant as well as novel NE marker, and the use of antibody SY 38 as a broad range marker for the study and diagnosis of NE neoplasms is proposed."
02/12/2013 - "These assessments were performed in the cortex and in the hippocampus, two regions known to subserve functional recovery after stroke and were coupled to the study of synaptophysin expression, a marker of synaptogenesis. "
01/01/2012 - "In addition, there was significant increase in vascular and synaptophysin immunoreactivity in stroke areas of rats that received In-111 labeled hUTC. "
08/25/2006 - "Here, we tested whether intra-carotid infusion of bone marrow stromal cells promotes synaptophysin expression and neurological functional recovery after stroke in rats. "
04/01/2012 - "Niaspan treatment of stroke in T1DM-MCAo rats significantly improved functional outcome after stroke and increased SMI-31, Bielschowsky silver and synaptophysin expression in the ischemic brain compared to saline treated T1DM-MCAo rats (p<0.05). "
11/11/2015 - "Despite the absence of neuroprotection, daidzein improved motor/gait function in chronic stroke and elevated synaptophysin expression. "
|3.||Alzheimer Disease (Alzheimer's Disease)
01/01/2010 - "In this study the process of synapse degeneration was investigated by measuring the synaptophysin content of cultured neurones incubated with the prion derived peptide (PrP82-146) or with Abeta1-42, a peptide thought to trigger pathogenesis in Alzheimer's disease. "
10/05/2005 - "In this study, we show that Abeta reduction by active or passive Abeta immunization protects against the progressive loss of synaptophysin in the hippocampal molecular layer and frontal neocortex of a transgenic mouse model of Alzheimer's disease. "
02/01/2015 - "Thr181, Ser202/Thr205, and Ser262), as well as synaptophysin in the temporal and frontal cortices of 18 VaD, 16 Alzheimer disease (AD), and 16 normal age-matched control subjects. "
01/01/2014 - "DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease."
01/01/2012 - " The density of presynaptic markers of synaptic communication and plasticity, especially synaptophysin (SYP), is significantly correlated with cognitive decline and the progression of Alzheimer's disease (AD), indicating that synaptic protection is an important therapeutic strategy for AD. "
|4.||Carcinoid Tumor (Carcinoid)
12/01/2011 - "The findings of the pathological examination revealed an atypical carcinoid tumor that was immunopositive for chromogranin and synaptophysin. "
10/01/2011 - "We studied the clinical, morphological, and immunohistochemical features in 9 primary renal carcinoid tumors from multiple institutions with particular emphasis on immunohistochemical findings, in particular, expression of paired box gene 2 and paired box gene 8. All 9 cases expressed at least 1 neuroendocrine marker (CD56, synaptophysin, chromogranin). "
03/01/2008 - "Carcinoid tumors showed strong immunoreactivity for synaptophysin and chromogranin, but no immunoreactivity for OCT4, CD30, c-kit, TTF-1, and CDX2. "
02/01/2007 - "Chromogranin and synaptophysin are excellent discriminatory markers for carcinoid tumor, and CD56 is neither sufficiently sensitive nor specific enough for this differential diagnosis to warrant its use in routine practice."
04/01/2002 - "All four carcinoid tumors were immunoreactive with chromogranin and synaptophysin. "
11/01/2007 - "Fourteen days postcastration, the remaining epithelial cells and adenocarcinoma cells were nonproliferative and lacked detectable SV40-Tag or synaptophysin expression. "
01/01/2007 - "CDX2, mCEA, CD56, synaptophysin, NSE and chromogranin can help differentiate it from non-endocrine poorly differentiated adenocarcinoma. "
01/01/2002 - "The adenocarcinoma stained strongly for CK7, CK 20, MIB-1, and focally for chromogranin and synaptophysin. "
09/01/2001 - "Four of 25 cases (16%) of adenocarcinomas were positive for MAP-2 and synaptophysin. "
06/01/2015 - "However, unlike most basal cell adenocarcinomas, this tumor demonstrated high grade morphology, showed no true ductal or myoepithelial component, and also showed a tendency towards neuroectodermal phenotype with focal rosette formation, CD99 and weak synaptophysin immunoreactivity. "
|3.||Phosphopyruvate Hydratase (Enolase)
|4.||Proteins (Proteins, Gene)
|5.||Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)
|6.||Glial Fibrillary Acidic Protein
|7.||S100 Proteins (S 100 Protein)
|8.||Brain-Derived Neurotrophic Factor (BDNF)
|9.||Calcium-Calmodulin-Dependent Protein Kinase Type 2
|2.||Drug Therapy (Chemotherapy)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|5.||Surgical Instruments (Clip)